Advertisement

Tumor Biology

, Volume 36, Issue 8, pp 6113–6124 | Cite as

Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population

Research Article

Abstract

The data on the outcome of breast invasive lobular carcinoma (ILC) are conflicting. In addition, the prognostic effect of molecular subtypes on ILC remains unclear. In this study, the clinicopathological and prognostic data between 269 ILC and 816 invasive ductal carcinoma (IDC) cases in a Chinese population were extensively compared, with a median follow-up time of 7.8 years. Compared with the IDC group, ILC tumors had more lymph node invasion, hormonal receptor positivity, and human epidermal growth factor receptor 2 (HER2) negativity. ILC patients showed overall survival (OS) and recurrence/metastasis-free survival (RFS) rates similar to those of IDC patients but exhibited worse disease-free survival (DFS) rate because of the higher rate of contralateral breast cancer (BC). Further analysis showed that OS, RFS, and DFS were similar between ILC and IDC patients in the subgroups of luminal A and triple-negative BC with HER2 negativity but were worse in ILC patients than those in IDC patients in the subgroups of luminal B and HER2 overexpression with positive HER2 expression. Multivariate analysis indicated HER2 positivity as an independent risk factor for OS, RFS, and DFS of ILC patients, which increased the risk in the ILC group than that in IDC group. The interaction of HER2 and ILC was also defined as an independent risk factor for OS, RFS, and DFS of the entire population. In conclusion, overexpression of HER2 exhibited stronger negative effect on the prognosis of ILC patients than that in IDC patients, suggesting that treatment targeting HER2 is crucial for this BC subgroup.

Keywords

Breast cancer Lobular carcinoma Prognosis Molecular subtypes 

Notes

Conflicts of interest

None

References

  1. 1.
    Colleoni M, Russo L, Dellapasqua S. Adjuvant therapies for special types of breast cancer. Breast. 2011;20 Suppl 3:S153–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Guiu S, Wolfer A, Jacot W, Fumoleau P, Romieu G, Bonnetain F, et al. Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions? Crit Rev Oncol Hematol. 2014;92(3):235–57.CrossRefPubMedGoogle Scholar
  3. 3.
    Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736–47.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20(8):1319–29.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Colleoni M, Rotmensz N, Maisonneuve P, Mastropasqua MG, Luini A, Veronesi P, et al. Outcome of special types of luminal breast cancer. Ann Oncol. 2012;23(6):1428–36.CrossRefPubMedGoogle Scholar
  6. 6.
    Jung SY, Jeong J, Shin SH, Kwon Y, Kim EA, Ko KL, et al. The invasive lobular carcinoma as a prototype luminal A breast cancer: a retrospective cohort study. BMC Cancer. 2010;10:664.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Schoon IM, Arvidsson S. Surgery in patients aged 80 years and over. A retrospective comparative study from 1981 and 1987. Eur J Surg. 1991;157(4):251–5.PubMedGoogle Scholar
  8. 8.
    Li CI, Anderson BO, Porter P, Holt SK, Daling JR, Moe RE. Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer. 2000;88(11):2561–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Zeng H, Zheng R, Zhang S, Zou X, Chen W. Female breast cancer statistics of 2010 in China: estimates based on data from 145 population-based cancer registries. J Thorac Dis. 2014;6(5):466–70.PubMedPubMedCentralGoogle Scholar
  10. 10.
    DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62.CrossRefPubMedGoogle Scholar
  11. 11.
    Sikora MJ, Jankowitz RC, Dabbs DJ, Oesterreich S. Invasive lobular carcinoma of the breast: patient response to systemic endocrine therapy and hormone response in model systems. Steroids. 2013;78(6):568–75.CrossRefPubMedGoogle Scholar
  12. 12.
    Rakha EA, Ellis IO. Lobular breast carcinoma and its variants. Semin Diagn Pathol. 2010;27(1):49–61.CrossRefPubMedGoogle Scholar
  13. 13.
    Berx G, Cleton-Jansen AM, Strumane K, de Leeuw WJ, Nollet F, van Roy F, et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene. 1996;13(9):1919–25.PubMedGoogle Scholar
  14. 14.
    Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90.CrossRefPubMedGoogle Scholar
  15. 15.
    Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;14(16):5158–65.CrossRefPubMedGoogle Scholar
  17. 17.
    Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10(4):R65.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol. 2010;220(2):263–80.PubMedGoogle Scholar
  19. 19.
    Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am. 2003;83(4):803–19.CrossRefPubMedGoogle Scholar
  20. 20.
    Henson DE, Ries L, Freedman LS, Carriaga M. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer. 1991;68(10):2142–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008;26(18):3006–14.CrossRefPubMedGoogle Scholar
  22. 22.
    Iorfida M, Maiorano E, Orvieto E, Maisonneuve P, Bottiglieri L, Rotmensz N, et al. Invasive lobular breast cancer: subtypes and outcome. Breast Cancer Res Treat. 2012;133(2):713–23.CrossRefPubMedGoogle Scholar
  23. 23.
    DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252–71.CrossRefPubMedGoogle Scholar
  24. 24.
    Azim HA, Ibrahim AS. Breast cancer in Egypt, China and Chinese: statistics and beyond. J Thorac Dis. 2014;6(7):864–6.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.CrossRefPubMedGoogle Scholar
  26. 26.
    Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6(3):R149–56.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Ko SS. Chronological changing patterns of clinical characteristics of Korean breast cancer patients during 10 years (1996–2006) using nationwide breast cancer registration on-line program: biannual update. J Surg Oncol. 2008;98(5):318–23.CrossRefPubMedGoogle Scholar
  28. 28.
    Fu L, Tsuchiya S, Matsuyama I, Ishii K. Clinicopathologic features and incidence of invasive lobular carcinoma in Japanese women. Pathol Int. 1998;48(5):348–54.CrossRefPubMedGoogle Scholar
  29. 29.
    Ohta T, Tsujimoto F, Nakajima Y, Fukuda M, Takag M. Ultrasonographic findings of invasive lobular carcinoma differentiation of invasive lobular carcinoma from invasive ductal carcinoma by ultrasonography. Breast Cancer. 2005;12(4):304–11.CrossRefPubMedGoogle Scholar
  30. 30.
    Talman ML, Jensen MB, Rank F. Invasive lobular breast cancer. Prognostic significance of histological malignancy grading. Acta Oncol. 2007;46(6):803–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Li CI, Weiss NS, Stanford JL, Daling JR. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer. 2000;88(11):2570–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Biglia N, Mariani L, Sgro L, Mininanni P, Moggio G, Sismondi P. Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment. Endocr Relat Cancer. 2007;14(3):549–67.CrossRefPubMedGoogle Scholar
  33. 33.
    Wasif N, Maggard MA, Ko CY, Giuliano AE. Invasive lobular vs ductal breast cancer: a stage-matched comparison of outcomes. Ann Surg Oncol. 2010;17(7):1862–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Hussien M, Lioe TF, Finnegan J, Spence RA. Surgical treatment for invasive lobular carcinoma of the breast. Breast. 2003;12(1):23–35.CrossRefPubMedGoogle Scholar
  35. 35.
    Fernandez B, Paish EC, Green AR, Lee AH, Macmillan RD, Ellis IO, et al. Lymph-node metastases in invasive lobular carcinoma are different from those in ductal carcinoma of the breast. J Clin Pathol. 2011;64(11):995–1000.CrossRefPubMedGoogle Scholar
  36. 36.
    Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403–10.CrossRefPubMedGoogle Scholar
  37. 37.
    Cao AY, Huang L, Wu J, Lu JS, Liu GY, Shen ZZ, et al. Tumor characteristics and the clinical outcome of invasive lobular carcinoma compared to infiltrating ductal carcinoma in a Chinese population. World J Surg Oncol. 2012;10:152.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol. 2005;23(1):41–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Nagao T, Kinoshita T, Hojo T, Tsuda H, Tamura K, Fujiwara Y. The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics. Breast. 2012;21(3):289–95.CrossRefPubMedGoogle Scholar
  40. 40.
    Weigelt B, Geyer FC, Natrajan R, Lopez-Garcia MA, Ahmad AS, Savage K, et al. The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol. 2010;220(1):45–57.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.National Clinical Research Center for Cancer, The Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Key Laboratory of Cancer Prevention and Therapy, TianjinTianjin Medical University Cancer Institute and HospitalTianjinChina
  2. 2.Modern Distance Education CollegeNankai UniversityTianjinPeople’s Republic of China
  3. 3.Public LaboratoryTianjin Medical University Cancer Institute and HospitalTianjinChina
  4. 4.Second Department of Breast TumorTianjin Medical University Cancer Institute and HospitalTianjinChina

Personalised recommendations